QNCX Quince Therapeutics, Inc.
Healthcare$1.20+9.09%ClosedMarket Cap: $6.7M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.35
P/S
0.00
EV/EBITDA
0.21
DCF Value
$-2.24
FCF Yield
-647.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
1823.5%
ROA
-124.1%
ROIC
-280.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-11.1M | $35.9M | $— | — |
| Q4 null | $0.00 | NaN% | $-19.4M | $-39.5M | $— | — |
| FY null | $0.00 | -Infinity% | $-50.4M | $-84.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-13.4M | $-13.4M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-9.9M | $-16.0M | $— | — |
| Q1 null | $0.00 | NaN% | $-14.9M | $-15.0M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-10.1M | $-12.5M | $— | — |
| FY null | $0.00 | NaN% | $-57.3M | $-56.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-5.9M | $-5.5M | $— | — |
| Q2 null | $0.00 | NaN% | $-28.2M | $-27.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-11.2M | $-11.1M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-8.3M | $-8.9M | $-0.22 | — |